Molecular profiling of the tumor using CARIS MI panel revealed methylated MGMT promoter, wild-type P53/IDH1/IDH2, intact PTEN/ATRX, MSI stable, TMB low, BRAFV600E mutation, and positive expression of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) (60%) by immunohistochemistry with WHO 2021 diagnosis of glioblastoma. This evidence concerns the gene IDH2 and neoplasm.